eASC pipeline


An adipose-derived allogeneic stem cell suspension for the treatment of complex perianal fistulas in Crohn's disease patients. On July 4, 2016, TiGenix entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States.

Cx601 summary


An intravenously-administered product of allogeneic expanded adipose-derived stem cells in development.

Cx611 summary


An adipose-derived allogeneic stem cell product candidate for the treatment of autoimmune diseases via a proprietary technique of intra-lymphatic administration.

Cx621 summary

Add this page to your PDF You have added 0 page(s) to your PDF. Download your PDF